Jim Mahoney, CEO, leaves Surface Logix

Keith Dionne fills CEO role at Surface Logix [October 14, 2008]

Agios Pharma closes $33M in Series A funding [July 7, 2008]

Agios forms largest cancer metabolism research lab in Cambridge [November 24, 2008]

Quanterix lands SBIR grant for early cancer detection [October 1, 2008]

Drug development company Surface Logix announced that current CEO and president Jim Mahoney has decided to step down from his position. In the interim, ARCH Venture Partners' managing director Steven Gillis will take the reins as executive chairman.

Mahoney will continue to serve as a consultant for the company while pursuing other interests.

In January, Boston-based Surface Logix completed Phase 2a clinical trials of its SLx-4090 for high cholesterol and its SLx-2101 for hypertension. The company landed a $52 million Series D round of financing in April 2007 to fund clinical development of its small molecule drug candidates.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.